{"id":10274,"date":"2019-09-20T13:54:32","date_gmt":"2019-09-20T11:54:32","guid":{"rendered":"https:\/\/udic.es\/?p=10274"},"modified":"2019-09-20T13:54:32","modified_gmt":"2019-09-20T11:54:32","slug":"we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/","title":{"rendered":"We started an intravenous antiamyloid therapy in mild Alzheimer&#8217;s"},"content":{"rendered":"<p>Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the open label extension for the patients who participated in this phase II study. We also started the development of the phase III clinical trial with this antiamyloid monoclonal antibody of EISAI \/ Biogen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the open label extension for the patients who participated in this phase II study. We also started the development of the phase III clinical trial with this antiamyloid monoclonal antibody of EISAI&#8230;<\/p>\n","protected":false},"author":4,"featured_media":9333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129],"tags":[],"class_list":["post-10274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzeimer-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>We started an intravenous antiamyloid therapy in mild Alzheimer&#039;s - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"We started an intravenous antiamyloid therapy in mild Alzheimer&#039;s - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-20T11:54:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"5056\" \/>\n\t<meta property=\"og:image:height\" content=\"1752\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"SUSANA ANDRADE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"SUSANA ANDRADE\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\"},\"author\":{\"name\":\"SUSANA ANDRADE\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\"},\"headline\":\"We started an intravenous antiamyloid therapy in mild Alzheimer&#8217;s\",\"datePublished\":\"2019-09-20T11:54:32+00:00\",\"dateModified\":\"2019-09-20T11:54:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\"},\"wordCount\":65,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg\",\"articleSection\":[\"Alzeimer\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\",\"url\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\",\"name\":\"We started an intravenous antiamyloid therapy in mild Alzheimer's - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg\",\"datePublished\":\"2019-09-20T11:54:32+00:00\",\"dateModified\":\"2019-09-20T11:54:32+00:00\",\"description\":\"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg\",\"width\":5056,\"height\":1752,\"caption\":\"Proyectos2 1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"We started an intravenous antiamyloid therapy in mild Alzheimer&#8217;s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\",\"name\":\"SUSANA ANDRADE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"caption\":\"SUSANA ANDRADE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"We started an intravenous antiamyloid therapy in mild Alzheimer's - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/","og_locale":"en_US","og_type":"article","og_title":"We started an intravenous antiamyloid therapy in mild Alzheimer's - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the","og_url":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2019-09-20T11:54:32+00:00","og_image":[{"width":5056,"height":1752,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg","type":"image\/jpeg"}],"author":"SUSANA ANDRADE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"SUSANA ANDRADE"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/"},"author":{"name":"SUSANA ANDRADE","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03"},"headline":"We started an intravenous antiamyloid therapy in mild Alzheimer&#8217;s","datePublished":"2019-09-20T11:54:32+00:00","dateModified":"2019-09-20T11:54:32+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/"},"wordCount":65,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg","articleSection":["Alzeimer"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/","url":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/","name":"We started an intravenous antiamyloid therapy in mild Alzheimer's - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg","datePublished":"2019-09-20T11:54:32+00:00","dateModified":"2019-09-20T11:54:32+00:00","description":"Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the","breadcrumb":{"@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Proyectos2-1.jpg","width":5056,"height":1752,"caption":"Proyectos2 1"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/we-started-an-intravenous-antiamyloid-therapy-in-mild-alzheimers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"We started an intravenous antiamyloid therapy in mild Alzheimer&#8217;s"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03","name":"SUSANA ANDRADE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","caption":"SUSANA ANDRADE"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10274"}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=10274"}],"version-history":[{"count":1,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10274\/revisions"}],"predecessor-version":[{"id":10275,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10274\/revisions\/10275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9333"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=10274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=10274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=10274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}